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Abstract 45 
Objectives 46 
Atrial fibrillation (AF) reduces survival and quality of life (QoL). It can be treated at the time of major 47 
cardiac surgery by ablation procedures ranging from simple pulmonary vein isolation to a full maze 48 
procedure. The aim of this study is to evaluate the impact of adjunct AF surgery as currently performed on 49 
sinus rhythm (SR) restoration, survival, QoL and cost-effectiveness. 50 
Methods 51 
In a multicentre, phase III, pragmatic, double-blind, parallel-arm randomised controlled trial, 352 cardiac 52 
surgery patients with >3 months of documented AF were randomised to surgery with or without adjunct 53 
maze or similar AF ablation between 2009 and 2014. Primary outcomes were SR restoration at 1 year and 54 
quality-adjusted life years (QALYs) at 2 years. Secondary outcomes included SR at 2 years, overall and 55 
stroke-free survival, medication, QoL, cost-effectiveness and safety.   56 
Results 57 
More maze patients were in SR at 1 year (odds ratio (OR) 2.06; 95% confidence interval (CI) 1.20-3.54; 58 
p=0.009). At 2 years the OR increased to 3.24 (95%CI 1.76-5.96). QALYs were similar at 2 years (maze – 59 
control: -0.025, p=0.6319). Significantly fewer maze patients were anticoagulated from 6 months 60 
postoperatively. Stroke rates were 5.7% (maze) and 9.1% (controls) (p=0.3083). There was no significant 61 
difference in stroke-free survival (HR=0.99, 95%CI 0.64, 1.53, p= 0.949), nor in serious adverse events, 62 
operative or overall survival, cardioversion, pacemaker implantation, NYHA, EQ-5D-3L and SF-36. Mean 63 
additional maze cost per patient was £3533 (95% CI: £1321 - £5746). Cost-effectiveness was not 64 
demonstrated at 2 years.   65 
Conclusion 66 
Adjunct AF surgery is safe and increases SR restoration and costs, but not survival or QoL up to 2 years. 67 
Continued follow-up will provide information these outcomes in the longer term.  68 
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Introduction 69 
The prevalence of atrial fibrillation (AF) is 1-2% in the developed world , rising with age and comorbidity1. 70 
UK prevalence is 7.2% after age 65 and 10.3% after 75 2 and will rise further with life expectancy.  71 
Symptoms include palpitations, chest pain, dizziness and breathlessness. Loss of atrial contractility increases 72 
the risk of thromboembolic stroke 3. Anticoagulation reduces stroke but increases bleeding risk 4. Atrial 73 
function loss may cause or exacerbate heart failure. AF has substantial impact on care and resources.  74 
 75 
AF pathophysiology is now better understood:  triggered most often by pulmonary vein foci, it is maintained 76 
through macro-re-entry circuits of 4-5 cm in diameter5, leading to the development of the Cox-maze 77 
procedure in the 1980s 6: through median sternotomy with cardiopulmonary bypass, the atria are cut and 78 
sutured to achieve pulmonary vein electrical isolation and interruption of macro-re-entry circuits. Despite 79 
success in restoring sinus rhythm (SR)7, this challenging procedure is usually reserved for severely 80 
symptomatic patients. Worldwide, the number of cut-and-sew Cox-maze procedures is extremely small in 81 
relation to AF prevalence.   82 
 83 
Less demanding methods for achieving some or all of the electrical blocks of the Cox-maze procedure use 84 
energy sources (heat, cold or radiofrequency) to ablate atrial tissue: easier, quicker and safer, but costly.  85 
Many cardiac surgery patients have AF. Whether they should routinely have adjunct AF surgery is unknown. 86 
Current practice varies widely between surgeons and hospitals. AF surgery increases SR restoration rate and 87 
decreases anti-arrhythmic medication use8-10. However, the impact on patient-relevant outcomes, such as 88 
survival and health-related QoL (HRQoL) is uncertain. Cost-effectiveness analyses have mixed results 11, 12, 89 
are limited by lack of HRQoL evidence in the short and medium term (1-5 years) and economic models are 90 
not robust. Amaze aimed to evaluate clinical and HRQoL outcomes and cost-effectiveness of this technology 91 
by comparing AF surgery as an adjunct to cardiac surgery with cardiac surgery alone.  92 
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Methods 93 
Amaze was a phase III, pragmatic, multicentre, double blind, parallel arm, randomised controlled superiority 94 
trial (RCT) in 11 cardiac surgical centres. Thirty surgeons participated with at least 2 years’ experience in 95 
AF surgery.   96 
Patient recruitment  97 
Consecutive cardiac surgery patients with a history of AF were screened. Inclusion criteria were: age ≥18, 98 
elective or urgent cardiac surgery (coronary, valve, combined, other surgery requiring cardiopulmonary 99 
bypass), documented history (>3 months) of AF (non-paroxyxmal or paroxysmal). Exclusion criteria were: 100 
previous cardiac operations, emergency or salvage operations, off-pump surgery, unavailability for follow-101 
up and inability to consent.  102 
Randomisation 103 
Group allocation (1:1) was computer-generated by the trial statistician, using permuted block randomisation 104 
(sizes 6 and 8), stratified by surgeon and planned procedure. Randomisation to planned cardiac surgery 105 
(control arm) or planned cardiac surgery with additional maze or similar ablation procedure (maze arm) was 106 
on operation day.  107 
Blinding 108 
Operating room staff could not be blinded to treatment allocation. After surgery, procedure details were kept 109 
in sealed envelopes in patient notes and only retrieved in a clinical emergency. Patients, cardiologists 110 
assessing ECG results and researchers collecting HRQoL outcomes were unaware of treatment arm. 111 
Clinical management 112 
Operative and perioperative management followed local protocols and were identical in both arms. AF 113 
surgery in the intervention arm was conducted by an experienced surgeon. Amaze was a pragmatic trial 114 
evaluating AF ablation as currently performed, so ablation methods and lesion sets were left to the surgeon: 115 
any device in clinical use was permitted, including bipolar and unipolar radio-frequency, ‘cut-and-sew’, 116 
cautery, cryotherapy, ultrasound, laser and microwave. Lesion sets and devices used were recorded.  117 
Outcomes 118 
SR restoration at one year after surgery and quality-adjusted life years (QALYs) over 2 years were joint 119 
primary outcomes. SR restoration required absence of any AF on 4-day continuous ECG analysed by 120 
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cardiologists unaware of patient identity or treatment arm. QALYs over 2 years were estimated from serial 121 
utility measurements from the UK population valuation of the EuroQoL EQ-5D-3L at randomisation, 122 
discharge, 6 weeks, 6, 12 and 24 months postoperatively. Secondary outcomes were 2-year SR restoration, 123 
overall survival, stroke-free survival, hospital admission for haemorrhage, antiarrhythmic and anticoagulant 124 
drug usage, NYHA, HRQoL (SF-36), resource use and cost-effectiveness at 2 years. Pre-specified subgroup 125 
analyses explored outcome differences by AF type, surgeons, and cardiac procedure. Outcome by lesion sets 126 
and method of ablation were compared within the maze arm. 127 
Sample size 128 
AF surgery was considered effective if there was a significant impact on either 1-year SR rates or 2-year 129 
quality-adjusted survival. The target (200 patients per arm) was based on detecting a of 15% difference in 130 
the proportion of patients in SR at 1 year (45% versus 30%) or 1 additional month of quality-adjusted life 131 
(0.083 QALYs, standard deviation 0.3) over 2 years, with approximately 80% power, two-sided significance 132 
of 5% and up to 15% death/loss to follow-up. Because of slower-than-expected accrual, recruitment stopped 133 
at 352 patients (88% target) reducing the power to detect the proposed treatment effects to over 70% for 134 
primary outcomes. In order to guard against over-interpretation of hypothesis tests due to multiple 135 
testing we recommend that p-values between 0.025 and 0.05 are considered of borderline 136 
significance. 137 
 138 
Statistical analysis 139 
Primary outcome analysis was by intention to treat. SR restoration was analysed by logistic regression, 140 
including surgeon (random intercepts), baseline rhythm and planned procedure (fixed effects).  For QALYs, 141 
linear regression, including surgeon (random intercepts), baseline utility and treatment arm (fixed effects), 142 
was fitted to utilities post-treatment. For survivors with missing EuroQoL measurements, multiple 143 
imputation was used and QALY difference confidence interval estimated using non-parametric 144 
bootstrapping. No primary outcome discounting was applied and no adjustment made for multiplicity. 145 
Sensitivity to assumptions surrounding missing data mechanisms were explored with no changes in results. 146 
For primary outcomes, pre-specified subgroup effects were explored by including interaction terms, except 147 
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for surgeon where a random effect was applied to the treatment coefficient.  Lesions set effects were 148 
assessed in the maze arm against a reference category. Adverse events by intervention were categorised by 149 
severity and relationship to procedure.  Survival and stroke-free survival were analysed using Kaplan-Meier 150 
and Cox regression. SF-36 score analysis used linear regression, including time point, treatment arm, time-151 
by-treatment arm interaction, baseline scores (fixed effects), with random intercepts for patients. Anti-152 
arrhythmic and anti-coagulant use was tabulated by time and category and analysed by logistic regression.  153 
 154 
Economic Analysis 155 
Resource use data from primary admission (time in theatre, intensive care and wards, hospital transfer, 156 
diagnostics and antiarrhythmic, antiplatelet, anticoagulant and cardiac drugs) were extracted from records, 157 
supplemented by patient-reported post-discharge health service use. Resources were valued using national 158 
estimates (https://www.evidence.nhs.uk/formulary/bnf/current ;  http://www.drugtariff.nhsbsa.nhs.uk/ ; 159 
http://www.pssru.ac.uk/project-pages/unit-costs/2015/  ; https://www.gov.uk/government/publications/nhs-160 
reference-costs-2014-to-2015 /  ) literature (blood pressure monitoring and radiology)13, 14 and data from 161 
Papworth Hospital (operating room and device cost). High intensity focussed ultrasound was costed at £3000 162 
and other methods at £1250.  Type missingness was examined and replaced with mean or imputed values. 163 
Missing resource and utility data were imputed jointly using chained equations with predictive mean 164 
matching.  Costs and QALYs were discounted at 3.5% in year two. Incremental cost-effectiveness ratios 165 
(ICERs) relied on seemingly unrelated regression, controlling for baseline differences in age, gender, EQ-166 
5D-3L, AF and (for QALYs) the primary surgery. Probabilistic sensitivity analysis used bootstrapping. Cost-167 
effectiveness planes, acceptability curve and incremental net monetary benefit were estimated. Deterministic 168 
sensitivity analysis explored the impact of using of SF-6D QALYs, complete case analysis, truncating costs 169 
and discharge QALYs, excluding outliers and alternative imputation strategies.   170 
 171 
Results  172 
Between February 2009 and March 2014, 1013 patients were screened by 30 surgeons in 11 centres: 352 173 
were randomised (176 each) to control or maze arms. Thirteen patients (3.7%) did not receive allocated 174 
treatment: 11 maze (6.3%) due to technical issues; 2 control (1.1%) due to surgeon-perceived benefit after 175 
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randomisation (figure 1). One-year SR status was available for 141 maze (80%) and 145 control patients 176 
(82%), 2-year QALYs were known for 160 patients in each arm (91%). Loss-to-follow-up reasons were 177 
similar for the two groups (figure 1), which were also similar in demographics, symptomatic status, 178 
cardiovascular profile and operations performed (tables 1-2). The left atrial (LA) appendage was resected or 179 
excluded in 97 maze arm patients (55.1%) and in 53 control patients (30.1%) 180 
Primary outcome: sinus rhythm at 1 year 181 
Among cases with complete ECG data, 87 of 141 maze patients (61.7%) were in SR at 1 year versus 68 of 182 
145 (46.9%) controls (figure 2). In intention-to-treat analysis, the odds ratio (95%CI) for 1-year SR 183 
restoration for the maze arm was 2.06 (1.20, 3.54), p=0.0091. This increased from 1.6 (0.6, 4.0) for the first 184 
120 randomised patients to 2.9 (0.9, 9.6) for the final 71 patients randomised in the last 18 months. 185 
Primary outcome: quality-adjusted life years 186 
The unadjusted, undiscounted mean (95%CI) QALY over 2 years was 1.489 (1.416, 1.558) for the maze arm 187 
and 1.485 (1.403, 1.559) in the control arm. In intention-to-treat analysis, the adjusted mean difference 188 
(95%CI) in QALYs at 2 years (maze – control) was – 0.025 (- 0.129, 0.078, p=0.6319).  189 
Secondary outcomes 190 
At 2 years, 69 of 118 (58.5%) maze completers were in SR compared with 47 of 129 (36.4%) controls 191 
(figure 2). The adjusted odds ratio for SR at 2 years was 3.24 (95%CI 1.76, 5.96). Significantly fewer maze 192 
patients received anticoagulants from 6 months (appendix table A2) without a higher stroke rate: 13 strokes 193 
in 10 (5.7%) maze patients and 19 in 16 (9.1%) control patients; the difference of -3.4% (95%CI -14.1%, 194 
7.3%) was not significant (Fisher’s Exact Test p=0.3083), nor was the difference in stroke events between 195 
the two groups (log-linear model relative rate 0.68 (95%CI: 0.34, 1.39, p=0.292). Stroke-free survival was 196 
similar in the two arms (HR=0.99, 95%CI 0.64, 1.53, p= 0·949, figure 4). Fifteen patients (7 maze, 8 197 
control) already had permanent pacemakers at surgery. Maze did not increase the need for permanent 198 
pacemaker implantation after surgery (maze 15, control 17). Sixty (34.1%) maze patients required 65 199 
cardioversions and 67 (38.1%) control patients required 72 cardioversions. Immediate cardioversion success 200 
rates were similar (48/65 (73.8%) maze and 54/72 (75.0%) control). There was no significant difference in 201 
anti-arrhythmic drug use throughout follow-up (appendix table A2). There were no significant differences 202 
between the two arms in any of the following outcomes at any time point: NYHA, EQ-5D-3L and SF-36. 203 
Nashef AMAZE page 8 
8 
 
Safety 204 
Mean (SD) cross-clamp time was 5.1 minutes longer in the maze group (82.2 (37.2) versus 77.2 (48.6)) and 205 
bypass time 18.9 minutes longer (118.1 (43.4) versus 99.3 (41.8)). There were 5 (2.8%) operative deaths in 206 
the maze group and 9 (5.1%) among controls (p=0.414). Over the trial course there were 30 maze and 25 207 
control deaths (hazard ratio (95%CI): 1.23 (0.73, 2.10) p=0.437), so that adding AF surgery did not 208 
significantly affect early or late mortality (figure 3). 209 
There were 330 adverse events in 100 AF surgery patients and 333 in 111 controls  (each 60%). Of these 71 210 
(42.5%) maze and 84 (45.5%) control patients had at least one moderately severe event and 31 (18.6%) 211 
maze and 38 (20.5%) control patients had a severe event. Few events were ‘possibly related’ to treatment: 23 212 
in 17 maze patients (10.2%) and 28 in 19 control patients (10.3%); one patient admitted to hospital for atrial 213 
flutter (classed as ‘definitely related’ to treatment) was subsequently found to be in the control group. 214 
 215 
Subgroup analysis 216 
Pre-planned subgroup analysis showed no significant interaction between 1-year SR restoration and type of 217 
AF (paroxysmal or non-paroxysmal) or planned cardiac procedure (figure 5). Random intercepts analysis 218 
showed that SR restoration rates varied by surgeon across both arms, with an intra-class correlation 219 
coefficient of 0.089. In the maze arm, the highest odds for 1-year SR restoration occurred with a 220 
comprehensive LA lesion set including the mitral isthmus lesion. Adding right atrial (RA) lesions conveyed 221 
no further increase in SR restoration odds (to be interpreted cautiously because of confounding associations 222 
between lesion sets and surgeons). Post hoc analysis of LA appendage excision showed a significant 223 
interaction, being increasingly used as the trial progressed for the maze group but not controls.  224 
 225 
Cost-effectiveness 226 
Higher maze costs resulted from the ablation device, length of stay in critical care and readmissions (table 227 
3). The adjusted mean incremental maze cost was £3533 (95% CI: £1321 to £5746), significantly higher 228 
than control (p<0·01). The adjusted mean QALY difference was not significant (-0022, 95% CI: -01231 to 229 
00791, p=0.67, appendix table A3). No analyses suggested that maze was cost-effective at 2 years at £30,000 230 
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per QALY.  The smallest ICER was £53,538/QALY from an unplanned analysis limited to patients 231 
randomised in the second half of the trial (appendix figures A2-5).  232 
 233 
Discussion 234 
In this pragmatic, multicentre trial, 1-year and 2-year SR restoration rates were significantly higher for maze 235 
patients than controls and slightly higher than reported in a recent RCT meta-analysis15. SR restoration rate 236 
in the control group was higher than any previously reported through cardiac surgery alone 16, 17. Control 237 
patients received the same postoperative care as trial patients including postoperative cardioversion 238 
suggesting that, with a determined effort, cardiac surgery alone can restore SR in a third of patients at 2 239 
years, an outcome worth pursuing in the absence of adjunct AF surgery.  240 
 241 
The optimal lesion set remains controversial. The full Cox-maze lesion set is established 18, and if there is a 242 
‘dose-response’ relationship, SR restoration rates should be better with a more complete lesion. One RCT of 243 
AF surgery in mitral patients found no significant difference in SR restoration between the complete lesion 244 
set and pulmonary vein isolation alone 16 , although it was probably insufficiently powered to detect such a 245 
difference. Many surgeons carry out only parts of the full Cox-maze, and there is a wide range of lesion sets 246 
used. Terminology is unhelpful with such procedures variously described as maze, mini-maze, left atrial 247 
maze or simply AF ablation. Amaze showed higher SR restoration rates with a complete LA lesion set 248 
including the mitral annulus or ‘isthmus’ lesion, but did demonstrate the benefit of adding RA lesions, 249 
although the power to detect these differences was low and adding such lesions has little impact on operative 250 
time or complexity above a full LA lesion set.  251 
 252 
We found no QoL impact at 2 years, but this is relatively short follow-up, and cardiac surgery alone achieves 253 
such an increase in QoL 19 that it may be difficult to discern additional benefits from AF surgery at this 254 
stage. Two factors may modify this conclusion in future: there was significantly less anticoagulation of maze 255 
patients postoperatively with no increase in stroke rate, and the HESTER study20 showed LA contractile 256 
recovery in most but not all patients when maze restores SR. These results lend support to anticoagulation 257 
withdrawal when SR is restored after maze but the varying extent of LA contractile recovery suggests LA 258 
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function should be measured before contemplating withdrawal. Continued follow-up of Amaze patients will 259 
establish whether QoL and survival advantages accrue over time.  260 
 261 
The per-patient cost over 2 years was higher in the maze arm with no significant impact on discounted 262 
QALYs.  Deterministic and probabilistic sensitivity analyses confirmed this and the probability that maze 263 
would be cost-effective at 2 years was less than 5% and alternative assumptions do not alter this conclusion. 264 
 265 
Strengths and limitations 266 
Amaze is the largest randomised trial to date to evaluate adjunct AF surgery. It is unique in including all 267 
cardiac (not only mitral) procedures, in having both patients and outcome assessors blinded to treatment arm 268 
and in incorporating survival, stroke-free survival and QoL as outcome measures. The pragmatic design 269 
evaluated AF surgery as currently done in clinical practice, rather than what may be achievable in specialist 270 
centres. The number of participating units and surgeons, the variety of ablation devices and lesion sets and 271 
the interaction between these variables has improved result generalisability but reduced the power to draw 272 
firm conclusions about the optimal device and lesion set. 273 
 274 
Recruitment is a widespread RCT problem. Logistic delays, activity overestimation and rising awareness of 275 
AF surgery among patients and clinicians affected recruitment rate. Infrequent follow-up (6, 12, 24 months) 276 
is associated with underreporting of frequent events, illness severity, and intensive service use, but there is 277 
no recommended interval between follow-ups 21, 22. In Amaze, 95% of the difference in follow-up costs 278 
related to re-admissions (infrequent major events) making cost underestimation unlikely. The cost-279 
effectiveness analysis was limited to 2 years and may not reflect long-term benefits. 280 
 281 
Conclusion 282 
Adjunct AF surgery can be practised safely in a routine cardiac surgical setting and increases SR restoration 283 
up to 2 years after surgery. This electrophysiological success did not translate into better 2-year survival or 284 
QoL and the procedure is therefore not proven to be cost-effective at 2 years. Longer follow-up will 285 
determine whether AF surgery has an impact on these outcomes.   286 
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 374 
 375 
Tables 376 
Table 1. Baseline characteristics for patients randomised in the Amaze trial. SD: standard deviation, CCS: Canadian 377 
Cardiac Society. NYHA: New York Heart Association.  378 
 
Maze  
(n=176) 
Control 
(n=176) 
Total  
(n= 352) 
Age (years)    
mean (SD) 72.3 (7.53) 71.4 (7.81) 71.9 (7.67) 
range (50.0 , 86.0) (48.0 , 89.0) (48.0 , 89.0) 
Sex    
male (%) 112 (63.6%) 120 (68.2%) 232 (65.9%) 
female (%) 64 (36.4%) 56 (31.8%) 120 (34.1%) 
Body mass index    
mean (SD) 28.1 (5.27) 27.6 (4.62) 27.9 (4.96) 
range (17.4 , 46.0) (17.9 , 42.8) (17.4 , 46.0) 
Logistic EuroSCORE (%)   
mean (SD) 6.94 (5.489) 6.64 (4.869) 6.79 (5.184) 
range (0.88 , 30.41) (1.40 , 23.85) (0.88 , 30.41) 
CCS Class     
Class 0 125 (71.0%) 133 (75.6%) 258 (73.3%) 
Class 1 13 (7.4%) 17 (9.7%) 30 (8.5%) 
Class 2 21 (11.9%) 16 (9.1%) 37 (10.5%) 
Class 3 10 (5.7%) 8 (4.5%) 18 (5.1%) 
Class 4 1 (0.6%) 1 (0.6%) 2 (0.6%) 
Missing / not known 6 (3.4%) 1 (0.6%) 7 (2.0%) 
NYHA classification  
I 
 
31 (17.6%) 
 
30 (17.0%) 
 
61 (17.3%) 
II 74 (42.0%) 68 (38.6%) 142 (40.3%) 
III 59 (33.5%) 71 (40.3%) 130 (36.9%) 
IV 10 (5.7%) 6 (3.4%) 16 (4.5%) 
Missing / Not known 2 (1.1%) 1 (0.6%) 3 (0.9%) 
 379 
  380 
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Table 2.  Cardiovascular status at baseline of patients randomised in the Amaze trial  381 
(LVEF: left ventricular ejection fraction, MI: myocardial infarction, PCI: percutaneous coronary intervention, MVR: 382 
mitral valve repair or replacement; CABG: coronary artery bypass grafting; AVR: aortic valve replacement                                      383 
 
Maze  
(n=176) 
Control  
(n=176) 
Total  
(n=352) 
Left ventricular function    
   poor (LVEF <30%) 4 (2.3%) 8 (4.5%) 12 (3.4%) 
   moderate (LVEF 30 - 50%) 50 (28.4%) 56 (31.8%) 106 (30.1%) 
   good (LVEF > 50%) 122 (69.3%) 112 (63.6%) 234 (66.5%) 
Previous PCI 16 (9.1%) 14 (8.0%) 30 (8.5%) 
Congestive Cardiac Failure 5 (2.8%) 1 (0.6%) 6 (1.7%) 
Diabetes    
   Insulin-dependent 5 (2.8%) 7 (4.0%) 12 (3.4%) 
   Non-insulin-dependent  27 (15.3%) 17 (9.7%) 44 (12.5%) 
Hyperlipidaemia 70 (39.8%) 63 (35.8%) 133 (37.8%) 
Atrial fibrillation class    
   Paroxysmal  44 (25.0%) 48 (27.3%) 92 (26.1%) 
   Persistent  30 (17.0%) 19 (10.8%) 49 (13.9%) 
   Permanent 102 (58.0%) 109 (61.9%) 211 (59.9%) 
Atrial fibrillation history    
   0 -3 months  4 (2.3%) 2 (1.1%) 6 (1.7%) 
   3 - 6 months  25 (14.2%) 25 (14.2%) 50 (14.2%) 
   6 - 12 months 31 (17.6%) 23 (13.1%) 54 (15.3%) 
   > 12 months  115 (65.3%) 126 (71.6%) 241 (68.5%) 
   not known 1 (0.6%) - 1 (0.3%) 
Permanent pacemaker 7 (4.0%) 8 (4.5%) 15 (4.3%) 
Previous cardioversion 24 (13.6%) 23 (13.1%) 47 (13.4%) 
Previous ablation 3 (1.7%) 1 (0.6%) 4 (1.1%) 
Other arrhythmias  2 (1.1%) 2 (1.1%) 4 (1.1%) 
Anticoagulants  137 (77.8%) 137 (77.3%) 274 (77.6%) 
Anti-arrhythmics 145 (82.4%) 148 (84.1%) 293 (83.2%) 
Actual procedure category    
MVR 39 (22.2%) 48 (27.3%) 87 (24.7%) 
CABG 35 (19.9%) 34 (19.3%) 69 (19.6%) 
AVR 32 (18.2%) 23 (13.1%) 55 (15.6%) 
CABG+AVR 16 (9.1%) 21 (11.9%) 37 (10.5%) 
CABG+MVR 14 (8.0%) 13 (7.4%) 27 (7.7%) 
All others 40 (22.7%) 37 (21.0%) 77 (21.9%) 
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Table 3. Mean (standard deviation) of per-patient costs of resource use, with imputation 384 
 
Maze (n=176) Control (n=176) 
Difference 
(Maze-
Control) Health Service Use 
Mean cost / 
patient (£) 
Std. Dev. 
Mean cost / 
patient (£) 
Std. Dev. 
P
ri
m
ar
y
 A
d
m
is
si
o
n
 
Theatre use £5,225 £1,594 £4,949 £1,863 £276 
Ablation device £1,212 £408 £14 £133 £1,197 
Adult Critical Care £4,029 £7,600 £3,065 £5,586 £964 
Cardiac Ward £3,397 £4,661 £3,064 £2,014 £333 
Rehabilitation £48 £325 £148 £1,082 -£100 
Acute Trust £937 £6,105 £165 £1,409 £772 
 Sub total £14,847 £12,474 £11,404 £7194 £3,443 
 
Medication (whole trial period) £618 £1,584 £681 £2,765 -£63 
F
o
ll
o
w
-u
p
 
Readmissions £1,650 £4,192 £1,220 £2,994 £430 
Tests £388 £376 £344 £283 £44 
Healthcare Visits £1,179 £1,061 £1,193 £1,052 -£14 
 Sub total £3,217 £5,629 £2,757 £4,329 £460 
 Grand Total £18,681 £13,340 £14,842 £8,295 £3,839 
 385 
 386 
  387 
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Figure legends 388 
Figure 1. 389 
Patient flow through the Amaze trial  390 
 391 
 392 
Figure 2.  393 
Percentage of patients in sinus rhythm free from atrial fibrillation at 1 year and 2 years after randomisation 394 
 395 
 396 
Figure 3.   397 
Six-year cumulative mortality rate after patient randomisation in the Amaze trial 398 
 399 
 400 
Figure 4.  401 
Six-year cumulative mortality-or-stroke rate after patient randomisation in the Amaze trial 402 
 403 
 404 
Figure 5.  405 
Forest plot showing the odds ratio of sinus rhythm restoration at one year after randomisation for predefined 406 
subgroups in the Amaze trial 407 
 408 
 409 
  410 
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Figures 411 
Figure 1. Patient flow through the Amaze trial412 
 413 
  414 
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Figure 2. Percentage of patients in sinus rhythm free from atrial fibrillation at 1 year and 2 years after 415 
randomisation 416 
 417 
 418 
 419 
 420 
 421 
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Figure 3.  Six-year cumulative mortality rate after patient randomisation in the Amaze trial 423 
 424 
 425 
 426 
 427 
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Figure 4. Six-year cumulative mortality-or-stroke rate after patient randomisation in the Amaze trial 429 
 430 
 431 
 432 
 433 
 434 
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Figure 5. Forest plot showing the odds ratio of sinus rhythm restoration at one year after randomisation for 436 
predefined subgroups in the Amaze trial 437 
 438 
